Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market

Market Insights

The report titled “Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall ABSSSI treatment market along with the market size and estimates for the duration 2015–2025. The said research study covers an in-depth analysis of multiple market segments based on the type of infection, pathogen, drug, and different geographies. According to market experts, acute skin and skin structure infections (ABSSSI) comprise a set of bacterial infections that involve multiple layers of the skin and associated tissues. These infections tend to be more severe in nature than simple infections of the skin, and they usually require systemic antibacterial therapy and patient hospitalization. The majority of ABSSSIs are caused by gram-positive bacterial strains, especially Staphylococcus aureus. Gram-negative bacteria, on the other hand, are extremely important in certain types of infections as well as in hospital settings.

The global ABSSSI treatment market is divided into Delafloxacin, Vancomycin, Ceftaroline Fosamil, Telvancin, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, TMP-SMZ, and Others for the purposes of this study. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global ABSSSI treatment market is also segmented on the basis of type of infection into cellulitis, abscess, boil, cyst, surgical wound, and traumatic wound. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The global ABSSSI treatment market is classified according to pathogen type, which includes Methicillin-sensitive Staphylococcus aureus (MSSA), Methicillin-resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and Others. Market size estimates and forecasts for these segments for the period 2015–2025 are provided in terms of USD million, along with the respective compounded annual growth rates (CAGRs) for the period 2017–2025, considering 2016 as the base year.

The geographical segmentation of the ABSSSI treatment market comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. The market size and forecast for these segments during 2015–2025 and their CAGRs for the period 2017–2025 are provided in this report.

The ABSSSI treatment market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Furiex Pharmaceuticals, Inc., GlaxoSmithKline plc, Melinta Therapeutics, Inc., Debiopharm International S.A., MerLion Pharmaceuticals Pte Ltd., Durata Therapeutics, Inc., Paratek Pharmaceuticals, Inc., and Cempra, Inc., among others.

Based on the type of infection, the global acute bacterial skin and skin structure infections treatment market is segmented as follows:

• Cellulitis
• Abscess/Boil/Cyst
• Surgical Wound
• Traumatic Wound

In 2016, cellulitis was observed as the largest segment due to key driving factors such as the rising prevalence of multiple drug-resistant bacteria, increasing hospitalization due to medical awareness, mounting cases of hospital-acquired infection, and incessant research and development activities observed in the ABSSSI treatment market. Although the exact incidence of the disease is unknown, a few American studies have identified 24.6 cases per 1,000 people per year as potentially affected by cellulitis, accounting for 37.3% of the hospitalized population. During the forecast period of 2017–2025, surgical wounds are expected to grow at a significant rate due to key driving factors such as the rising prevalence of surgical site infections, the introduction of stringent policies associated with hospital environments by government agencies, and rising awareness associated with early diagnosis and treatment among physicians to treat multiple resistant bacterial infections.

Based on the type of drug, the global acute bacterial skin and skin structure infection (ABSSSI) treatment market are segmented as follows:

• Delafloxacin
• Vancomycin
• Ceftaroline family
• Telavancin
• Oritavancin
• Tedizolid
• Daptomycin
• Tigecycline
• Linezolid
• TMP-SMZ
• Others (Doxycycline, Levofloxacin, Metronidazole, and Others)

In 2016, vancomycin was observed as the largest market segment as it is the most preferred drug in the treatment of multiple resistant bacterial infections. The rising prevalence of nosocomial infections, high awareness associated with skin diseases and early diagnosis, and incessant research and development activities in the field of ABSSSI treatment In the near future, delafloxacin is expected to be the fastest-growing drug due to its exclusive approval against ABSSSI and high efficiency compared to existing drugs. The brand name of delafloxacin is Baxdela, owned by Melinta Therapeutics; according to studies, delafloxacin is a fluoroquinolone with activity against both gram-positive and gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), and is available in both intravenous (IV) and oral formulations.

Based on the type of pathogen, the global acute bacterial skin and skin structure infections treatment market is segmented as follows:

• Methicillin-sensitive Staphylococcus aureus (MSSA)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Beta-hemolytic Streptococcus
• Escherichia coli
• Enterococcus faecalis
• Pseudomonas aeruginosa
• Others

In 2016, MSSA and MRSA accounted for more than 50% of the market share due to key drivers such as the rising prevalence of multi-resistance bacterial infections, high public awareness associated with hospital-acquired infections, and incessant research and development in the field of ABSSSI treatment. According to the American Pharmacists Association, approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult. Thus, the prevalence of hospital-acquired infections is increasing, coupled with the stringent regulations and policies adopted by government bodies against hospitals that lack the means to maintain a sterile environment.

Based on the type of pathogen, the global acute bacterial skin and skin structure infections treatment market is segmented as follows:

• Methicillin-sensitive Staphylococcus aureus (MSSA)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• Beta-hemolytic Streptococcus
• Escherichia coli
• Enterococcus faecalis
• Pseudomonas aeruginosa
• Others

In 2016, MSSA and MRSA accounted for more than 50% of the market share due to key drivers such as the rising prevalence of multi-resistance bacterial infections, high public awareness associated with hospital-acquired infections, and incessant research and development in the field of ABSSSI treatment. According to the American Pharmacists Association, approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult. Thus, the prevalence of hospital-acquired infections is increasing, coupled with the stringent regulations and policies adopted by government bodies against hospitals that lack the means to maintain a sterile environment.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global ABSSSI Treatment Market Portraiture
2.1.1. Global ABSSSI Treatment Market, by Drug, 2016
2.1.2. Global ABSSSI Treatment Market, by Pathogen, 2016
2.1.3. Global ABSSSI Treatment Market, by Infection, 2016
2.1.4. Global ABSSSI Treatment Market, by Geography, 2016

Chapter 3. ABSSSI Treatment Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. ABSSSI: Epidemiology
3.3. ABSSSI Treatment: Future Trends
3.4. Drivers
3.5. Challenges
3.6. Opportunities
3.7. Attractive Investment Proposition, by Geography, 2016
3.8. Major Agreements, Partnerships and Collaborations
3.9. Competitive Landscape
3.9.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
4.1. Overview
4.1.1. Attractive Investment Proposition: Global ABSSSI Treatment Market, by Drug
4.2. Delafloxacin
4.3. Vancomycin
4.4. Ceftaroline fosamil
4.5. Telvancin
4.6. Oritavancin
4.7. Tedizolid
4.8. Daptomycin
4.9. Tigecycline
4.10. Linezolid
4.11. TMP-SMZ
4.12. Others (Doxycycline, Levofloxacin, Metronidazole, and Others)

Chapter 5. Global ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global ABSSSI Treatment Market, by Infection
5.2. Cellulitis
5.3. Abscess/Boil/Cyst
5.4. Surgical Wound
5.5. Traumatic Wound

Chapter 6. Global ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
6.1. Overview
6.1.1. Attractive Investment Proposition: Global ABSSSI Treatment Market, by Pathogen
6.2. Methicillin sensitive Staphylococcus aureus (MSSA)
6.3. Methicillin resistant Staphylococcus aureus (MRSA)
6.4. Beta-hemolytic Streptococcus
6.5. Escherichia coli
6.6. Enterococcus faecalis
6.7. Pseudomonas aeruginosa
6.8. Others

Chapter 7. Global ABSSSI Treatment Market: Pipeline Analysis
7.1. Overview
7.2. Phase III (Market estimations by 2025)
7.2.1. Ceftobiprole (Basilea Pharmaceutica)
7.2.2. MK-1986 (Merck Sharp & Dohme Corp.)
7.2.3. TR-701 FA (Trius Therapeutics LLC)
7.3. Phase II (Qualitative Information)
7.4. Phase I (Qualitative Information)
7.5. Preclinical Studies (Qualitative Information)

Chapter 8. Global ABSSSI Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
8.1. Overview
8.2. North America ABSSSI Treatment Market Analysis, 2015 – 2025
8.2.1. North America ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
8.2.2. North America ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
8.2.3. North America ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
8.2.4. North America ABSSSI Treatment Market, by Country, 2015 – 2025 (US$ Mn)
8.2.4.1. U.S.
8.2.4.2. Canada
8.3. Europe ABSSSI Treatment Market Analysis, 2015 – 2025
8.3.1. Europe ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
8.3.2. Europe ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
8.3.3. Europe ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
8.3.4. Europe ABSSSI Treatment Market, by Country, 2015 – 2025 (US$ Mn)
8.3.4.1. U.K.
8.3.4.2. Germany
8.3.4.3. France
8.3.4.4. Spain
8.3.4.5. Italy
8.3.4.6. Rest of Europe
8.4. Asia Pacific ABSSSI Treatment Market Analysis, 2015 – 2025
8.4.1. Asia Pacific ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
8.4.2. Asia Pacific ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
8.4.3. Asia Pacific ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
8.4.4. Asia Pacific ABSSSI Treatment Market, by Country, 2015 – 2025 (US$ Mn)
8.4.4.1. Japan
8.4.4.2. China
8.4.4.3. India
8.4.4.4. Rest of APAC
8.5. Latin America ABSSSI Treatment Market Analysis, 2015 – 2025
8.5.1. Latin America ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
8.5.2. Latin America ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
8.5.3. Latin America ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
8.5.4. Latin America ABSSSI Treatment Market, by Country, 2015 – 2025 (US$ Mn)
8.5.4.1. Brazil
8.5.4.2. Mexico
8.5.4.3. Rest of Latin America
8.6. Middle East & Africa (MEA) ABSSSI Treatment Market Analysis, 2015 – 2025
8.6.1. MEA ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
8.6.2. MEA ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
8.6.3. MEA ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
8.6.4. MEA ABSSSI Treatment Market, by Region, 2015 – 2025 (US$ Mn)
8.6.4.1. UAE
8.6.4.2. Saudi Arabia
8.6.4.3. South Africa
8.6.4.4. Rest of MEA

Chapter 9. Company Profiles
9.1. Furiex Pharmaceuticals, Inc.
9.1.1. Business Description
9.1.2. Financial Information (Subject to data availability)
9.1.3. Product Portfolio
9.1.4. Key Developments
9.2. GlaxoSmithKline plc
9.3. Melinta Therapeutics, Inc.
9.4. Debiopharm International S.A.
9.5. MerLion Pharmaceuticals Pte Ltd.
9.6. Durata Therapeutics, Inc.
9.7. Paratek Pharmaceuticals, Inc.
9.8. Cempra, Inc.
9.9. Abbott Laboratories, Inc.
9.10. Actelion Pharmaceuticals Ltd.
9.11. Albany Molecular Research, Inc.
9.12. Allergan plc.
9.13. AstraZeneca
9.14. Bayer AG
9.15. Macrolide Pharmaceuticals, Inc.
9.16. Merck & Co, Inc.
9.17. Pfizer, Inc.
9.18. Sanofi
9.19. Teva Pharmaceuticals Industries Ltd.
9.20. Zavante Therapeutics, Inc.

List of Figures

FIG. 1 ABSSSI Treatment: Market Segmentation
FIG. 2 Global ABSSSI Treatment Market Share, by Drug, 2016 (Value %)
FIG. 3 Global ABSSSI Treatment Market, by Infection, 2016 (US$ Mn)
FIG. 4 Global ABSSSI Treatment Market, by Pathogen, 2016 (US$ Mn)
FIG. 5 Global ABSSSI Treatment Market, by Geography, 2016 (Value %)
FIG. 6 Attractive Investment Proposition, by Geography, 2016
FIG. 7 Market Competition Landscape, by Key Players, 2016
FIG. 8 Global Delafloxacin Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Global Vancomycin Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Global Ceftaroline fosami Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 Global Telvancin Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 12 Global Oritavancin Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 13 Global Tedizolid Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 14 Global Daptomycin Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 15 Global Tigecycline Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 16 Global Linezolid Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 17 Global TMP-SMZ Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 18 Global Others Market in ABSSSI Treatment, 2015 – 2025 (US$ Mn)
FIG. 19 Global ABSSSI based Cellulitis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 20 Global ABSSSI based Abscess/Boil/Cyst Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 21 Global ABSSSI based Surgical Wound Treatment Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 22 Global ABSSSI based Traumatic Wound Treatment Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 23 Global Methicillin sensitive Staphylococcus aureus (MSSA) Treatment Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 24 Global Methicillin resistant Staphylococcus aureus (MRSA) Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 25 Global Beta-hemolytic Streptococcus Treatment Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 26 Global Escherichia coli Treatment Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 27 Global Enterococcus faecalis Treatment Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 28 Global Pseudomonas aeruginosa Treatment Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 29 Global Other Pathogens Treatment Market in ABSSSI, 2015 – 2025 (US$ Mn)
FIG. 30 Global Ceftobiprole Market in ABSSSI Treatment (Forecast by 2025) (US$ Mn)
FIG. 31 Global MK-1986 Market in ABSSSI Treatment (Forecast by 2025) (US$ Mn)
FIG. 32 Global TR-701 FA Market in ABSSSI Treatment (Forecast by 2025) (US$ Mn)
FIG. 33 U.S. ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 34 Canada ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 35 U.K. ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 36 Germany ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 37 France ABSSSI Treatment Market, 2015-2025 (US$ Mn)
FIG. 38 Spain ABSSSI Treatment Market, 2015-2025 (US$ Mn)
FIG. 39 Italy ABSSSI Treatment Market, 2015-2025 (US$ Mn)
FIG. 40 Rest of Europe ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 41 Japan ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 42 China ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 43 India ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 44 Rest of Asia Pacific ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 45 Brazil ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 46 Mexico ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 47 Rest of Latin America ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 48 UAE ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 49 Saudi Arabia ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 50 South Africa ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 51 Rest of Middle East and Africa ABSSSI Treatment Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
TABLE 2 Global ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
TABLE 3 Global ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
TABLE 4 Global ABSSSI Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
TABLE 6 North America ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
TABLE 7 North America ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
TABLE 8 North America ABSSSI Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Europe ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
TABLE 10 Europe ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
TABLE 11 Europe ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
TABLE 12 Europe ABSSSI Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Asia Pacific ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
TABLE 14 Asia Pacific ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
TABLE 15 Asia Pacific ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
TABLE 16 Asia Pacific ABSSSI Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 17 Latin America ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
TABLE 18 Latin America ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
TABLE 19 Latin America ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
TABLE 20 Latin America ABSSSI Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 21 Middle East and Africa ABSSSI Treatment Market, by Drug, 2015 – 2025 (US$ Mn)
TABLE 22 Middle East and Africa ABSSSI Treatment Market, by Infection, 2015 – 2025 (US$ Mn)
TABLE 23 Middle East and Africa ABSSSI Treatment Market, by Pathogen, 2015 – 2025 (US$ Mn)
TABLE 24 Middle East and Africa ABSSSI Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 25 Furiex Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 Melinta Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Debiopharm International S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 MerLion Pharmaceuticals Pte Ltd..: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 31 Durata Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Paratek Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 Cempra, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Abbott Laboratories, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Actelion Pharmaceuticals Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 36 Albany Molecular Research, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 37 Allergan plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 38 AstraZeneca : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 39 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 40 Macrolide Pharmaceuticals, Inc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 41 Merck & Co, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 42 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 43 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 44 Teva Pharmaceuticals Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 45 Zavante Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)